Journal article
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
Abstract
BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis.
METHODS: We did a randomised, prospective, double-blind, double-dummy, …
Authors
Maertens JA; Rahav G; Lee D-G; Ponce-de-León A; Sánchez ICR; Klimko N; Sonet A; Haider S; Vélez JD; Raad I
Journal
The Lancet, Vol. 397, No. 10273, pp. 499–509
Publisher
Elsevier
Publication Date
2 2021
DOI
10.1016/s0140-6736(21)00219-1
ISSN
0140-6736